Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business

Stock Track

2024-10-08

Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).

In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.

The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1164994522"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164994522\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1164994522?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 15:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164994522","market":"hk","top_or_hot":-1,"title":"Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business","media":"Stock Track","content":"<html><body><p>Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).</p>\n<p>In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.</p>\n<p>The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-08 15:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).</p>\n<p>In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.</p>\n<p>The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"","article_id":"1164994522","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164994522","pubTimestamp":1728373150,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of WuXi AppTec Co. Ltd.  plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies .In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"股票追踪由于细胞治疗业务的不确定性，药明康德股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).\nIn a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.\nThe announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}